Effectiveness of the use of biomarkers in the early detection of lung cancer: A systematic review of recent evidence (2020-2025)
DOI:
https://doi.org/10.47606/ACVEN/MV0304Keywords:
biomarkers, Lung cancer, early diagnosisAbstract
Introduction: Lung cancer represents a serious health problem. Objective: The objective of the research was to analyze the current evidence on the effectiveness of biomarkers in its early detection. Methodology: A systematic review was conducted, using the PRISMA 2020 method for the search process. The search was conducted in PubMed, Scopus, SpringerLink, and Google Scholar, applying filters for language, year, and type of publication. Twenty-five studies that met the inclusion criteria were included.. Results: Molecular and protein biomarkers, combined with liquid biopsy and artificial intelligence, show high efficacy in early detection, overcoming limitations of traditional methods. Conclusions: These findings support the progressive incorporation of biomarkers into population screening protocols and suggest future multicenter research for their clinical validation. To achieve effective implementation, it is necessary to address economic limitations, improve the standardization of protocols and validate their usefulness in multicenter studies, following the example of innovations already applied in other neoplasms
Downloads
References
Bade C, De la Cruz C. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clinics in Chest Medicine. 2020;41(1), 1-24. https://doi.org/10.1016/j.ccm.2019.10.001
Da Silva F, Nascimiento D, Salem A, Monteiro, A, Souza R. Evolución del Tabaquismo e Incidencia de Cáncer de Pulmón en el Brasil (2000-2020). Revista Brasileira de Cancerologia. 2025;71(1). https://doi.org/10.32635/2176-9745.RBC.2025v71n1.4864
Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45. https://doi.org/10.3322/caac.21871
Marquina F, Lévano C, Fuster D. Nuevos avances terapéuticos en pacientes con cáncer de pulmón inmunosuprimidos con enfermedades crónicas pulmonares en el periodo 2014-2022 a partir de la revisión de la literatura. Revista Española de Salud Pública. 2025;97(1), e1-e24. https://www.scielosp.org/pdf/resp/2023.v97/e202302015/es
Mazzone P, Silvestri G, Souter L, Caverly T, Kanne J, Katki H, Soylemez R, Detterbeck F. Screening for Lung Cancer CHEST Guideline and Expert Panel Report. Thoracic Oncology: Guideline and Consensus Statement. 2021;160(5), e427-e494. https://journal.chestnet.org/article/S0012-3692(21)01307-6/fulltext
Horne A, Harada K, Brown K, Min K, McDonald F, Price G, Putora P, Rothwell D, Faivre-Finn C. Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer. Journal of Thoracic Oncology. 2024;19(8), 1164-1185. https://doi.org/10.1016/j.jtho.2024.04.006
Merchán-Villafuerte K, Perez-Gonzales G, Velez G, Vera S. Biomarcadores y diagnóstico temprano de enfermedades autoinmunes en la infancia: avances y desafíos. Journal Scientific MQRInvestigar, 2024;8(1), 3451-3470. https://doi.org/10.56048/MQR20225.8.1.2024.3451-3470
Demera A, Holguín J, Macrillo C, Baquerizo A, Vidal S. Aplicaciones de la biotecnología en el diagnóstico temprano del cáncer mediante biomarcadores moleculares: Una revisión sistemática. Chinese Medical Journal Pulmonary and Critical Care Medicine. 2025;12(1), 2563–2581. https://doi.org/10.69639/arandu.v12i1.758
Emédico A, Da Silva J, Dos Santes J, Fontoura P, Vasconcelos J. Aplicação da inteligência artificial no diagnóstico e monitoramento do Câncer de Mama: uma revisão sistemática. Brazilian Journal of Health Review. 2024;7(5), e73198. https://doi.org/10.34119/bjhrv7n5-292
Davies M, Sato T, Ashoor H, Hou L, Liloglou T, Yang R, Field J. Plasma protein biomarkers for early prediction of lung cancer. eBioMedicine. 2023;93, 104686. https://doi.org/10.1016/j.ebiom.2023.104686
Moina A, Endara C. Evaluación crítica de sistemas citológicos en cáncer cervical: Revisión Bethesda y otros enfoques para diagnóstico eficaz. Revista Latinoamericana de Ciencias Sociales y Humanidades. 2024;5(1), 1190 – 1210. https://doi.org/10.56712/latam.v5i1.1666
García de Yébenes M, Carmona L. Biomarcadores: cómo lograr su consolidación en práctica clínica. Reumatología Clínica. 2024;20(7), 386-391. https://doi.org/10.1016/j.reuma.2024.05.005
Page, M., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., Mulrow, C., Shamseer, L., Tetzlaff, J., , Brennan, S., Chou, R., Glanville, J., Grimshaw, J., Hróbjartsson, A., Lalu, M., Li, T., Loder, E., Mayo-Wilson, E., McDonald, S., McGuinness, L., Stewart, L., Thomas, J., Tricco, A., Welch, V., Whiting, P., Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372, n71. https://doi.org/10.1136/bmj.n71
Jeong S, Farfán L, Jiménez J. Cómo se redacta un artículo de revisión sistemática. Cir Columna. 2024;2(2), 131-137. https://doi.org/10.35366/115863
Eliçora A, Güven B, Engin H, Tugba G, Fatih H. Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer? Journal of Cardiothoracic Surgery. 2025;20(92), 1-7. https://doi.org/10.1186/s13019-024-03296-4
Luo C, Lin Z, Huang F, Ning L, Yuan Y. Tumor-Educated Platelets lncRNA-STARD4-AS1 and ELOA-AS1 as Potential Novel Biomarkers for the Early Diagnosis of Non-Small Cell Lung Cancer. Cancer Management and Research. 2025;17,1-9. https://doi.org/10.2147/CMAR.S498516
Ashirbekov Y, Khamitova N, Satken K, Abaildayev A, Yeleussizov A, Yegenova L, Kairanbayeva A, Kadirshe D, Utegenova G, Jainakbayev N, Sharipov K. Circulating MicroRNAs as Biomarkers for the Early Diagnosis of Lung Cancer and Its Differentiation from Tuberculosis. Diagnostics. 2024;14 (23), 2684. https://doi.org/10.3390/diagnostics14232684
Arabnejad M, Tothill I, Chianella I. Impedimetric Biosensors for the Quantification of Serum Biomarkers for Early Detection of Lung Cancer. Biosensors. 2024;14(12), 624. https://doi.org/10.3390/bios14120624
Zare M, Nasir A, Wu X, Zhou L, Lu J, Huang J, Wang Y, Ma Y, Gao Y, Zhang J. Serum human epididymis Protein-4 outperforms conventional biomarkers in the early detection of non-small cell lung cancer. iScience. 2024;27(11), 111211. https://doi.org/10.1016/j.isci.2024.111211
Chen H, Ma Y, Xu J, Wang W, Hao L, Quan C, Yang F, Lu Y, Wu H, Qiu M. Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer. Cell Reports Medicine. 2024;5(4), 101499. https://doi.org/10.1016/j.xcrm.2024.101499
Duffy M. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction. Tumor Biology, 2023;46, S283-S295. https://doi.org/10.3233/TUB-220044
Mohamed E, García D, Hossini M, Qi S, Fletcher D, Hart S, Guinn B. Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis. 2024;45 (1), 1-22. https://doi.org/10.1093/carcin/bgad091
Gasparri R, Sabalic A, Spaggiari L. The Early Diagnosis of Lung Cancer: Critical Gaps in the Discovery of Biomarkers. Journal of Clinical Medicine. 2023;12(23), 7244. https://doi.org/10.3390/jcm12237244
Ren S, Zeng G, Yuling Y, Li, L, Tu H, Chai T, Hu L. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer. Heliyon. 2023;9(10), e20851. https://doi.org/10.1016/j.heliyon.2023.e20851
Zhou H, Liao J, Leng Q, Chinthalapally M, Dhilipkannah P, Jiang F. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer. Microorganisms. 2023;11(3), 582. https://doi.org/10.3390/microorganisms11030582
Dama E, Colangelo T, Fina E, Cremonesi M, Kallikourdis M, Veronesi G, Bianchi F. Biomarkers and Lung Cancer Early Detection: State of the Art. Cancers. 2021;13(15), 3919. https://doi.org/10.3390/cancers13153919
Lakhani D, Chen S, Antic S, Muterspaugh A, Cook C, Liu N, Shujat H, Jouan S, Winston B, Fieldas K, Nestrup J, Block S, Hinton A, Miller A, Atmajoana S, Helton J, Patel K, Balar A, Bianchi, ... Massion P. Establishing a cohort and a biorepository to identify biomarkers for early detection of lung cancer: The Nashville lung cancer screening trial cohort. ATS Journals. 2021;18(7), 1227–1234. https://doi.org/10.1513/AnnalsATS.202004-344OC
Gasparri R, Sedda G, Caminiti V, Maisonneuve P, Prisciandaro E, Spaggiari L. Urinary Biomarkers for Early Diagnosis of Lung Cancer. Journal of Clinical Medicine. 2021;10(8), 1723. https://doi.org/10.3390/jcm10081723
Yang S, Xia J, Yang Z, Xu M, Li S. Urinary Biomarkers for Early Diagnosis of Lung Cancer. Cancer Treatment and Research Communications, 2021;27, 100311. https://doi.org/10.1016/j.ctarc.2021.100311
Maharjan N, Thapa N, Tu J. Blood-based Biomarkers for Early Diagnosis of Lung Cancer: A Review Article. Journal of Nepal Medical Association. 2020;58(227), 519–524. https://doi.org/10.31729/jnma.5023
Tiwari, R. Breakthrough Biomarkers in Lung Cancer: Pioneering Early Detection and Precision Treatment Strategies. Chinese Journal of Applied Physiology. 2024;e20240034. http://47.94.85.12:8889/article/1859398224374390784
Xu Y, Dong X, Qin C, Wang F, Cao W, Li J, Yu Y, Zhao Liang, Tan F, Chen W, Li N, He J. Metabolic biomarkers in lung cancer screening and early diagnosis (Review). Oncology Letters. 2023;25(6), 265. https://doi.org/10.3892/ol.2023.13851
Bi L, Wang X, Li J, Li W, Wang Z. Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis. MedComm. 2025;6(3), e70080. https://doi.org/10.1002/mco2.70080
Chaudhary V, Taha B, Lucky Rustagi, S, Khosla A, Papakonstantinou P, Bhalla N. Nose-on-Chip Nanobiosensors for Early Detection of Lung Cancer Breath Biomarkers. ACS Sensors. 2024;9(9), 4469–4494. https://doi.org/10.1021/acssensors.4c01524
Abdel G, Ali E, Ahmed A, Hozayen W, Mohamed-Hussein A, Elnaggar M, Hetta H. Circulating miRNA-30a and miRNA-221 as Novel Biomarkers for the Early Detection of Non-Small-Cell Lung Cancer. Middle East Journal of Cancer. 2020;11(1), 50–58. https://doi.org/10.30476/mejc.2019.81242.0
Zhong Y, Ding X, Bian Y, Wang J, Zhou W, Wang X, Li P, Shen Y, Wang J, Zhang C, Wang C. Discovery and validation of extracellular vesicle-associated miRNAs as noninvasive detection biomarkers for early-stage non-small-cell lung cancer. Molecular Oncology. 2020;15(9), 2439-2452. https://doi.org/10.1002/1878-0261.12889
Yin J, Hu W, Gu H, Fang J. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer. Journal of cancer. 2021;12(4), 1258–1269. https://doi.org/10.7150/jca.49647
Song K, Balasaheb S, Dashrath S, Kim J, Kim H, Kim T. Detection and Quantification of Tp53 and p53-Anti-p53 Autoantibody Immune Complex: Promising Biomarkers in Early-Stage Lung Cancer Diagnosis. Biosensors. 2022;12(2), 127. https://doi.org/10.3390/bios12020127
Bibikova M, Jianbing F. Liquid biopsy for early detection of lung cancer. Chinese Medical Journal Pulmonary and Critical Care Medicine. 2023;1(4), 200–206. https://doi.org/10.1016/j.pccm.2023.08.005
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Berly Cahuascanco-Quispe, Angel Mamani-Ruelas, Katherine Milagros Quispe-Medina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
